Physician profile
Barbara Obrien
NPI 1821097304
$1,065.40
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $132 · 2021: $202 · 2022: $111 · 2024: $22.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $262.55 | 2019-2022 | |
| Ucb, INC. | $121.94 | 2019-2022 | |
| Novo Nordisk INC | $119.05 | 2019 | |
| Abbvie INC. | $90.89 | 2020-2021 | |
| Lumendi LLC | $85.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.41 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.62 | 2019-2024 | Entyvio |
| Allergan, INC. | $46.01 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $44.81 | 2019-2020 | |
| Qol Medical, LLC | $30.34 | 2019 | |
| Braintree Laboratories, INC. | $27.00 | 2022 | |
| Gilead Sciences, INC. | $22.89 | 2019 | |
| Ethicon US, LLC | $19.91 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.77 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.78 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.